Posted by Michael Wonder on 09 Nov 2020
Impel Neuropharma announces FDA submission of new drug application for INP104 for the acute treatment of migraine
9 November 2020 - The INP104 new drug application is supported by results from the Phase 3 STOP 301 trial.
Impel NeuroPharma today announced that it has submitted a new drug application for INP104 (dihydroergotamine mesylate) or DHE to the U.S. FDA for the acute treatment of migraine headaches with or without aura in adult patients.
INP104 uses the Company's proprietary precision olfactory delivery technology, a novel delivery system that uniquely targets the vascular-rich upper nasal space.
